What is the appropriate first‑line antibiotic and dosing for a 67‑year‑old woman on chronic hemodialysis with a pan‑susceptible Acinetobacter baumannii infection of an internal jugular catheter, presenting with leukocytosis (white blood cell count 30,000) with 90% neutrophils, weakness and altered sensorium?

Antibiotic Selection for Pan-Susceptible Acinetobacter baumannii Catheter-Related Bloodstream Infection in a Hemodialysis Patient

For this 67-year-old hemodialysis patient with pan-susceptible Acinetobacter baumannii catheter-related bloodstream infection presenting with severe sepsis (leukocytosis 30,000, altered mental status), high-dose ampicillin-sulbactam is the first-line antibiotic, dosed at 3g sulbactam (6g ampicillin-sulbactam) every 8 hours as a 4-hour infusion, administered after each hemodialysis session.

Rationale for Ampicillin-Sulbactam as First-Line Therapy

• Sulbactam has intrinsic antimicrobial activity against A. baumannii independent of its β-lactamase inhibitor properties, making it the preferred β-lactam option when the isolate is susceptible. 1

• For pan-susceptible strains, ampicillan-sulbactam demonstrates superior safety compared to polymyxins (colistin), with nephrotoxicity rates of 15.3% versus 33%, which is particularly critical in a hemodialysis patient. 1, 2

• Clinical outcomes with ampicillin-sulbactam are equivalent to carbapenems for severe A. baumannii infections, including bacteremia. 1, 3

• Carbapenems (imipenem, meropenem, doripenem) remain drugs of choice in areas with low carbapenem resistance, but sulbactam is preferred when susceptible due to its narrower spectrum and better safety profile. 1, 2, 4

Specific Dosing Regimen for Hemodialysis Patients

• Administer 3g sulbactam (equivalent to 6g ampicillin-sulbactam 2:1 formulation) every 8 hours as a 4-hour extended infusion. 1, 2, 3

• The 4-hour infusion optimizes pharmacokinetic/pharmacodynamic properties and allows treatment of isolates with MIC up to 8 mg/L. 1, 3

• Schedule doses immediately after hemodialysis sessions to maximize drug exposure, as both ampicillin and sulbactam are dialyzable. 5

• Total daily sulbactam dose of 9g (18g ampicillin-sulbactam) is the minimum recommended for severe infections and bacteremia. 1, 2, 3

Why Not Polymyxins for This Patient

• Colistin should be reserved for strains resistant to all β-lactams, fluoroquinolones, and tigecycline—not for pan-susceptible isolates. 5, 1

• For patients on intermittent hemodialysis requiring colistin, the dose would be 2 million IU colistimethate sodium (CMS) every 12 hours with a normal loading dose of 6-9 million IU, with dialysis performed toward the end of the dosing interval. 5

• Polymyxin B would require a loading dose of 2-2.5 mg/kg followed by 1.5-3 mg/kg/day without dose adjustment for hemodialysis, but is unnecessary given pan-susceptibility. 5, 6

• The significantly higher nephrotoxicity risk with polymyxins (33% versus 15.3%) makes them inappropriate first-line choices when effective alternatives exist. 1, 2

Combination Therapy Considerations

• Monotherapy with high-dose ampicillin-sulbactam is appropriate for this pan-susceptible isolate once clinical stability is achieved. 1, 3

• Combination therapy with two in-vitro active agents is reserved for carbapenem-resistant strains, septic shock with predicted mortality >25%, or clinical failure on monotherapy. 1, 2

• Avoid colistin plus rifampicin (lacks proven benefit, increases hepatotoxicity) and colistin plus vancomycin (increases nephrotoxicity without added benefit). 1, 2

Treatment Duration and Monitoring

• Maintain antimicrobial therapy for a minimum of 14 days for catheter-related bloodstream infection with severe sepsis and altered mental status. 1, 2

• Remove or replace the infected internal jugular catheter as soon as feasible, as catheter retention is associated with treatment failure in A. baumannii bacteremia. 7

• Monitor for clinical response with repeat blood cultures to document clearance, typically obtained 48-72 hours after initiating appropriate therapy. 2

• Assess renal function before each hemodialysis session, though ampicillin-sulbactam carries lower nephrotoxicity risk than alternatives. 1, 3

Critical Pitfalls to Avoid

• Do not use standard doses of 6g/day sulbactam (12g/day ampicillan-sulbactam) for severe infections—this is inadequate for critically ill patients with bacteremia. 1, 3

• Never use ertapenem for A. baumannii infections despite it being a carbapenem, as it lacks activity against this pathogen. 2, 3

• Avoid tigecycline as monotherapy for bacteremia due to suboptimal serum concentrations (Cmax 0.87 mg/L) and documented poor outcomes in A. baumannii bacteremia. 5, 2

• Do not delay appropriate therapy while awaiting final susceptibility results in critically ill patients—initiate empiric coverage based on local resistance patterns and patient risk factors. 2

• Verify sulbactam MIC by E-test or broth microdilution if available, as automated susceptibility methods are unreliable for sulbactam. 1

Alternative Regimen if Ampicillin-Sulbactam Unavailable

• If ampicillin-sulbactam is not available, use a carbapenem (meropenem 2g every 8 hours as extended infusion, or imipenem 500mg every 6 hours) given the pan-susceptible profile. 2, 4, 7

• Adjust carbapenem doses for hemodialysis: administer supplemental doses after each dialysis session. 5